TXB4-BC3

N/A

Report date: 2025/01/26 17:34:51

Base Information

Drug NameTXB4-BC3

Drug Alias Nameanti-transferrin receptor 1/anti-PD-L1 bispecific mAb (Ossianix)TXB4-BC3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 modulatorsTransferrin receptor protein 1 modulators

TargetsProgrammed death-ligand 1Transferrin receptor protein 1

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOssianix Inc

China Registration ClassN/A

Develop Information

Active CompaniesOssianix Inc

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A